NLRP3 and myocardial infarction: To justify clinical trials with selective NLRP3 inhibitors in patients with acute MI or HTx it is important to expand our knowledge about the exact mechanisms of the NLRP3 inflammasome and perform translational research in large animal models to fully evaluate the potential of these selective inhibitors.